Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 5:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Honey Clear all
Withdrawn Phase 1Phase 2 Interventional

Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma

NCT03100877
View directory record Official record
Conditions
Plasma Cell Leukemia in Remission, Plasma Cell Myeloma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Filgrastim, Laboratory Biomarker Analysis, Lenalidomide, pheresis, Melphalan, Palifermin, Total Marrow Irradiation
Procedure · Drug · Biological + 2 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Sep 17, 2026, 5:18 AM EDT
Terminated Phase 2 Interventional Results available

Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer

NCT00670748
View directory record Official record
Conditions
Metastatic Melanoma, Metastatic Renal Cell Cancer, Metastatic Cancer
Interventions
Anti-NY ESO-1 T-cell receptor PBL, aldesleukin, Cyclophosphamide, fludarabine phosphate, ALVAC NY ESO-1 vaccine
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 66 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Sep 17, 2026, 5:18 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)

NCT03347123
View directory record Official record
Conditions
Solid Tumors
Interventions
Epacadostat, Nivolumab, Ipilimumab, Lirilumab
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
5
States / cities
Birmingham, Alabama • Los Angeles, California • Santa Monica, California + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2022 · Synced Sep 17, 2026, 5:18 AM EDT
Completed Phase 2 Interventional Results available

Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies

NCT04191187
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Biphenotypic Acute Leukemia, Undifferentiated Leukemia, Prolymphocytic Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Myeloproliferative Neoplasm, Relapsed Large Cell Lymphoma, Mantle Cell Lymphoma, Hodgkin Lymphoma, Burkitt Lymphoma, Relapsed T-Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Relapsed Small Lymphocytic Lymphoma, Relapsed Marginal B-cell Lymphoma, Relapsed Follicular Lymphoma, Lymphoplasmacytic Lymphoma
Interventions
Fludarabine, Melphalan, Total Body Irradiation
Drug · Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Sep 17, 2026, 5:18 AM EDT
Completed Phase 3 Interventional Results available

Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis

NCT01078454
View directory record Official record
Conditions
Light Chain Deposition Disease, Primary Systemic Amyloidosis
Interventions
melphalan, dexamethasone, bortezomib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
209
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Aurora, Colorado + 140 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2022 · Synced Sep 17, 2026, 5:18 AM EDT
Completed Phase 1 Interventional

Effect of Honey and Dextromethorphan on Nocturnal Cough and Sleep

NCT00127686
View directory record Official record
Conditions
Cough, Respiratory Tract Infections
Interventions
Dextromethorphan, Buckwheat Honey
Drug
Lead sponsor
Penn State University
Other
Eligibility
2 Years to 18 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 23, 2017 · Synced Sep 17, 2026, 5:18 AM EDT
Completed Phase 1 Interventional

Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma

NCT01163357
View directory record Official record
Conditions
Autologous Hematopoietic Stem Cell Transplant Recipient, Loss of Chromosome 17p, Plasma Cell Leukemia, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
bortezomib, fludarabine phosphate, melphalan, total marrow irradiation, tacrolimus, sirolimus, peripheral blood stem cell transplantation, laboratory biomarker analysis
Drug · Other · Radiation + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Sep 17, 2026, 5:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparison of Esophageal Clearance Times of Oral Budesonide Preparations

NCT02125851
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Xanthan Gum, Honey
Other
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2014 · Synced Sep 17, 2026, 5:18 AM EDT
Terminated Not applicable Interventional Results available

A Clinical Evaluation of a Honey Impregnated Dressing at Removing Necrotic Tissue From Chronic Wounds

NCT03412929
View directory record Official record
Conditions
Wound Heal, Necrotic Tissue Removal
Interventions
Honey Impregnated Dressing
Device
Lead sponsor
Medline Industries
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Lake in the Hills, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Sep 17, 2026, 5:18 AM EDT
Not listed No phase listed Observational

Development of Novel, Biophysically Designed Fluids for Swallowing Disorders

NCT03131869
View directory record Official record
Conditions
Deglutition Disorders
Interventions
Thickened Beverages Nectar, Thickened Beverage Honey
Other
Lead sponsor
Swallow Solutions
Industry
Eligibility
55 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Madison, Wisconsin • Marshfield, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Sep 17, 2026, 5:18 AM EDT
Completed Early Phase 1 Interventional

Impact of Probiotics on Oral Microbiota in Older Adults With Dysphagia

NCT03682094
View directory record Official record
Conditions
Dysphagia
Interventions
VSL#3
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
65 Years to 99 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Sep 17, 2026, 5:18 AM EDT
Active, not recruiting Phase 2 Interventional

Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy

NCT00871013
View directory record Official record
Conditions
Myeloma
Interventions
Melphalan, Velcade, Thalidomide, Dexamethasone, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2027
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 17, 2026, 5:18 AM EDT
Withdrawn Phase 2 Interventional

A Pilot Study of the Combination of Melphalan, Bortezomib, Thalidomide and Dexamethasone (MEL-VTD)

NCT00577668
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Melphalan, Velcade, Thalidomide, Dexamethasone
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated May 2, 2011 · Synced Sep 17, 2026, 5:18 AM EDT
Completed Phase 2 Interventional Results available

Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma

NCT02506959
View directory record Official record
Conditions
Plasma Cell Leukemia, Plasmacytoma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Gemcitabine Hydrochloride, Melphalan, Panobinostat, Peripheral Blood Stem Cell Transplantation, Pharmacological Study
Procedure · Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Sep 17, 2026, 5:18 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

New Mexico Honey Wound Treatment Research Study

NCT01748318
View directory record Official record
Conditions
Community-acquired Methicillin-resistant Staphylococcus Aureus Infection
Interventions
New Mexico Honey, Bactrim DS
Drug
Lead sponsor
R. Stephen Rankin, M.D.
Individual
Eligibility
16 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Farmington, New Mexico
Source: ClinicalTrials.gov public record
Updated May 9, 2016 · Synced Sep 17, 2026, 5:18 AM EDT
Terminated Phase 1 Interventional

Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment

NCT00800150
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
fludarabine phosphate, melphalan, nonmyeloablative allogeneic hematopoietic stem cell transplantation, intensity-modulated radiation therapy, tomotherapy, total marrow irradiation, total nodal irradiation
Drug · Procedure · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
16 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2015 · Synced Sep 17, 2026, 5:18 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Leptospermum Scoparium Honey and Wound Care for Pressure Ulcers

NCT02689310
View directory record Official record
Conditions
Pressure Ulcers
Interventions
Leptospermum scoparium honey, Standard of Care Treatment
Other
Lead sponsor
New York City Health and Hospitals Corporation
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Sep 17, 2026, 5:18 AM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

The Effect of Nutritional Supplementation on Actinic Purpura: A Pilot Study

NCT06840574
View directory record Official record
Conditions
Skin Health, Skin Aging of Face and Hands, Healthy, Ecchymosis
Interventions
Cyruta Plus: A Whole-Food Based Vitamin C supplement containing organic buckwheat (aerial parts) juice powder, organic buckwheat flour, bovine adrenal Cytosol™ extract, oat flour, honey, ascorbic acid, Low Dose Vitamin C, High Dose Vitamin C
Dietary Supplement
Lead sponsor
Standard Process Inc.
Industry
Eligibility
55 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 17, 2026, 5:18 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Influence of Honey-flavored Yogurt on Low-grade Inflammation and Gut Health in Middle to Older Aged Women.

NCT04248127
View directory record Official record
Conditions
Overweight
Interventions
Honey sweetened yogurt, Sugar sweetened yogurt
Other
Lead sponsor
University of California, Davis
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 17, 2026, 5:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

NECTAR Study: Nectar (Honey) Effects on Comfort, Thoughts, and Regularity

NCT04187950
View directory record Official record
Conditions
Gastrointestinal Dysfunction, Physiological Stress, Cognition - Other
Interventions
Yogurt with B. lactis and added honey, Yogurt with heat-inactivated B. lactis and added cane sugar
Dietary Supplement
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
22 Years to 64 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Sep 17, 2026, 5:18 AM EDT
Completed Phase 1 Interventional

SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)

NCT04291079
View directory record Official record
Conditions
Cancer
Interventions
SRK-181, anti-PD-(L)1 antibody therapy
Biological
Lead sponsor
Scholar Rock, Inc.
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
18
States / cities
Fullerton, California • La Jolla, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 17, 2026, 5:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Honey Used as Adjunct Therapy to Tylenol for Post-Op Tonsillectomy Patients

NCT03931395
View directory record Official record
Conditions
Tonsillectomy
Interventions
Honey, Standard of Care
Dietary Supplement · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
2 Years to 17 Years
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 31, 2021 · Synced Sep 17, 2026, 5:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Eating Peanuts for Health

NCT01886326
View directory record Official record
Conditions
Obesity, Overweight, Hyperlipidemia
Interventions
Consumption of 42 grams of peanuts daily
Other
Lead sponsor
Purdue University
Other
Eligibility
18 Years to 50 Years
Enrollment
196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Sep 17, 2026, 5:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study of the MEL 80 Excimer Laser Using LASIK in the Treatment of Mixed Astigmatism

NCT00761826
View directory record Official record
Conditions
Mixed Astigmatism
Interventions
MEL 80 Mixed Astigmatism Treatment
Device
Lead sponsor
Carl Zeiss Meditec, Inc.
Industry
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
5
States / cities
San Diego, California • Greenwood Village, Colorado • Kansas City, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Sep 17, 2026, 5:18 AM EDT